Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (21569)	6/1/1998 12:41:00 AM
From: Webhead	Respond to of 32384

Hey Biotech Jim ( no relation to "earthworm jim" I hope!), Funny you should mention BPV E5 since the lab I'm in identified and characterized the E5:PDGFR transformation pathway. Though I don't work with E5, I think the elucidation of this biochemical pathway was a beautiful piece of work. I am a bit curious as to why you're interested in it since BPV doesn't infect people and I am unaware of any human paradigms for an endogeneous, E5-like protein. (Lot's of poor postdocs have lost lots of sleep trying the get the HPV E5 protein to actually DO anything so HPVE5 doesn't seem a likely candidate for human disease). Sugen has a PDGF receptor inhibitor that kills kinase activity (SU101 I believe), that is in clinical testing for a variety of cancers (not an endorsement, just information).